COCP

Latest SEC Filings & News for COCP

3 most recent filings and news items mentioning COCP. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/COCP/news?limit=20"

Pull COCP filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

Cocrystal Pharma appoints James Sapirstein as Chief Executive Officer

Cocrystal Pharma announced the appointment of James Sapirstein as Chief Executive Officer effective June 3, 2026, with a $265,000 annual salary and 235,000 stock options. The leadership change signals organizational transition and provides equity incentive alignment with company

View filing at SEC.gov →

Cocrystal Pharma appoints James Sapirstein as CEO

Cocrystal Pharma appointed James Sapirstein as Chief Executive Officer effective immediately, replacing co-CEOs Sam Lee and Jim Martin. Sapirstein brings 23 product launches and extensive antiviral development experience from prior roles at Contravir, Tobira, and Gilead Sciences.

View filing at SEC.gov →

Cocrystal discovers pan-viral inhibitors targeting hantavirus, bunyavirus, influenza

Cocrystal Pharma announced discovery of novel direct-acting antivirals with pan-viral activity against hantavirus, bunyavirus and influenza, targeting a conserved viral replication enzyme region. The announcement addresses significant unmet medical needs for hantavirus and bunyav

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.